BioSpace News Archive

CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy, is celebrating Dyne Therapeutics’ successful initial public offering and subsequent listing on NASDAQ.

Owens & Minor, Inc. announced the implementation of a succession plan within its Board of Directors.

ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP Securities MedTech Bio Summit. Axogen’s presentation during this virtual summit is scheduled for Thursday, October 1, 2020 at 11:00 a.m. ET. The presentation will be webcast live and can be accessed thro

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced the addition of David J. Woodhouse, Ph.D., to the Board of Directors.

Brickell Biotech, Inc. announced that its Japanese development partner, Kaken Pharmaceutical Co., Ltd., received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the treatment of primary axillary hyperhidrosis.

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences

TELA Bio, Inc. announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

Closed non-brokered and oversubscribed Private Placements for total gross proceeds of $2.6 million, including $353,000 from management and Board members